Regeneron (REGN) Tops Q3 EPS by $1.23, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Regeneron Reports Third Quarter 2020 Financial and Operating Results
November 5, 2020 6:30 AM ESTTARRYTOWN, N.Y., Nov. 5, 2020 /PRNewswire/ --
Third quarter 2020 revenues increased 32% to $2.29 billion versus third quarter 2019(4) Third quarter 2020 EYLEA® U.S. net sales increased 11% to $1.32 billion versus third quarter 2019 Third quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, increased 69% to $1.07 billion versus third quarter 2019 Third quarter 2020 GAAP diluted EPS was $7.39 and non-GAAP diluted EPS(1) was $8.36 REGN-COV2 trial in the COVID-19 outpatient setting met primary and key secondary endpoints FDA accepted for priority review Libtayo® (cemiplimab-rwlc) for both advanced... More